P80 natural essence spray and lozenges provide respiratory protection against Influenza A, B, and SARS-CoV-2.
Antiviral lozenges
Antiviral spray
Epithelial barrier model
Influenza
P80
SARS-CoV-2
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
received:
13
07
2023
accepted:
01
02
2024
medline:
29
2
2024
pubmed:
29
2
2024
entrez:
28
2
2024
Statut:
epublish
Résumé
Seasonally circulating viruses, such as Influenza, as well as newly emerging viruses and variants thereof, and waning immunity urge the need for safe, easy-to-use and inexpensive drugs to protect from these challenges. To prevent transmission of these viruses and subsequent excessive inflammatory reactions on mucous membranes, we tested the efficacy of the natural essence P80 as spray and in form of lozenges against respiratory infections caused by SARS-CoV-2 variants of concern (VoCs), influenza A (H3N2) and influenza B (Victoria). P80 natural essence, a Dimocarpus longan extract, shielded highly differentiated human airway epithelia from SARS-CoV-2 wildtype and Omicron variant as well as Influenza A and B infection and dampened inflammation by down-modulating pro-inflammatory cytokine and anaphylatoxin secretion. A single application of P80 natural essence spray maintained tissue integrity long-term. This also significantly reduced the release of infectious viral particles and the secretion of IP10, MCP1, RANTES and C3a, all of which mediate the migration of immune cells to the sites of infection. Even P80 lozenges dissolved in distilled water or non-neutralizing saliva efficiently prevented SARS-CoV-2 and Influenza-induced tissue destruction. Consequently, our in vitro data suggest that P80 natural essence can act as antiviral prophylactic, both in form of nasal or oral spray and in form of lozenges, independent of circulating respiratory challenges.
Identifiants
pubmed: 38419061
doi: 10.1186/s12931-024-02718-0
pii: 10.1186/s12931-024-02718-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102Subventions
Organisme : Austrian Science Fund
ID : P34070-B
Organisme : Austrian Science Fund
ID : P33510-B
Informations de copyright
© 2024. The Author(s).
Références
Zaderer V, Posch W, Gstir R, Filipek PA, Bonn GK, Aramwit P, Huber LA, Wilflingseder D. P80 natural essence exerts efficient Anti-HIV-1- as Well as Adjuvant effects in DCs. Vaccines (Basel) 2021. 9.
Apriyanto DR, Aoki C, Hartati S, Hanafi M, Kardono LB, Arsianti A, Louisa M, Sudiro TM, Dewi BE, Sudarmono P, Soebandrio A, Hotta H. Anti-hepatitis C Virus activity of a crude extract from Longan (Dimocarpus longan Lour.) Leaves. Jpn J Infect Dis. 2016;69:213–20.
doi: 10.7883/yoken.JJID.2015.107
pubmed: 26255732
Bai Y, Jia X, Huang F, Zhang R, Dong L, Liu L, Zhang M. Structural elucidation, anti-inflammatory activity and intestinal barrier protection of longan pulp polysaccharide LPIIa. Carbohydr Polym. 2020;246:116532.
doi: 10.1016/j.carbpol.2020.116532
pubmed: 32747231
Wang Z, Gao X, Li W, Tan S, Zheng Q. Phenolic content, antioxidant capacity, and alpha-amylase and alpha-glucosidase inhibitory activities of Dimocarpus longan lour. Food Sci Biotechnol. 2020;29:683–92.
doi: 10.1007/s10068-019-00708-3
pubmed: 32419967
Yi Y, Liao ST, Zhang MW, Zhang RF, Deng YY, Yang B, Wei ZC. Immunomodulatory activity of polysaccharide-protein complex of longan (Dimocarpus longan Lour.) Pulp. Molecules. 2011;16:10324–36.
doi: 10.3390/molecules161210324
pubmed: 22158685
pmcid: 6264376
Yi Y, Zhang MW, Liao ST, Zhang RF, Deng YY, Wei ZC, Tang XJ, Zhang Y. Structural features and immunomodulatory activities of polysaccharides of longan pulp. Carbohydr Polym. 2012;87:636–43.
doi: 10.1016/j.carbpol.2011.08.034
pubmed: 34663015
Ryabkova VA, Churilov LP, Shoenfeld Y. Influenza infection, SARS, MERS and COVID-19: cytokine storm - the common denominator and the lessons to be learned. Clin Immunol. 2021;223:108652.
doi: 10.1016/j.clim.2020.108652
pubmed: 33333256
Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22:77–84.
doi: 10.1038/s41577-021-00665-1
pubmed: 34912108
Dichtl S, Zaderer V, Kozubowski V, Halim AE, Lafon H, Lanser E, Weiss L, Lass-Florl G, Wilflingseder C, D. and, Posch W. Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections. Front Med (Lausanne). 2022;9:1005589.
doi: 10.3389/fmed.2022.1005589
pubmed: 36250084
Posch W, Vosper J, Noureen A, Zaderer V, Witting C, Bertacchi G, Gstir R, Filipek PA, Bonn GK, Huber LA, Bellmann-Weiler R, Lass-Florl C, Wilflingseder D. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia. J Allergy Clin Immunol. 2021;147:2083–97. e2086.
doi: 10.1016/j.jaci.2021.03.038
pubmed: 33852936
pmcid: 8056780
Posch W, Vosper J, Zaderer V, Noureen A, Constant S, Bellmann-Weiler R, Lass-Florl C, Wilflingseder D. ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia. mBio 2021. 12.
Zaderer V, Dichtl S, Weiler B, Lass Florl R, Posch C, W. and, Wilflingseder D. ColdZyme(R) protects airway epithelia from infection with BA.4/5. Respir Res. 2022;23:300.
doi: 10.1186/s12931-022-02223-2
pubmed: 36316674
Zaderer V, Dichtl S, Posch W, Abiatari I, Bonn GK, Jakschitz T, Huber LA, Kurzchalia TV, Wilflingseder D. GlyPerA effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events. Respir Res. 2023;24:88.
doi: 10.1186/s12931-023-02397-3
pubmed: 36949547
pmcid: 10032620
Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T, Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T, Kageyama T, Takeda M. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020;117:7001–3.
doi: 10.1073/pnas.2002589117
pubmed: 32165541
pmcid: 7132130
Eder J, Bermejo-Jambrina M, Vlaming KE, Kaptein TM, Zaderer V, Kemper EM, Wilflingseder D, Reitsma S, de Bree GJ, Cohn DM, Geijtenbeek TBH. Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2. mBio 2022. 13: e0255822.
Sinkovits G, Mezo B, Reti M, Muller V, Ivanyi Z, Gal J, Gopcsa L, Remenyi P, Szathmary B, Lakatos B, Szlavik J, Bobek I, Prohaszka ZZ, Forhecz Z, Csuka D, Hurler L, Kajdacsi E, Cervenak L, Kiszel P, Masszi T, Valyi-Nagy I, Prohaszka Z. Complement overactivation and consumption predicts In-Hospital mortality in SARS-CoV-2 infection. Front Immunol. 2021;12:663187.
doi: 10.3389/fimmu.2021.663187
pubmed: 33841446
pmcid: 8027327
Stenmark KR, Frid MG, Gerasimovskaya E, Zhang H, McCarthy MK, Thurman JM, Morrison TE. Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement. Pulm Circ. 2021;11:20458940211015799.
doi: 10.1177/20458940211015799
pubmed: 34046161
pmcid: 8138299
Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, Liu J, Guo X, Huang C, Jiao Y, Zhu F, Zhu B, Cui L. Serum Cytokine and Chemokine Profile in Relation to the severity of Coronavirus Disease 2019 in China. J Infect Dis. 2020;222:746–54.
doi: 10.1093/infdis/jiaa363
pubmed: 32563194
Mulla S, Molla MMA, Ahmed SMA, Akhtaruzzaman AKM, Saleh AA, Anwar S. Association of interferon gamma inducible protein-10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1 alpha, interleukin-6, and rs12252 single nucleotide polymorphism of interferon-induced transmembrane protein-3 gene with the severity of COVID-19 infection. Egypt J Intern Med. 2022;34:53.
doi: 10.1186/s43162-022-00141-9
pubmed: 35822078
pmcid: 9264736